Source:http://linkedlifedata.com/resource/pubmed/id/16643206
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2006-4-28
|
| pubmed:abstractText |
The aim of the study was to assess the incidence and the cumulative probability of cytolytic and cholestatic hepatotoxicity during antiretroviral treatment in a group of HIV HCV haemophiliacs. We evaluated 47 patients that received 246 courses of antiretroviral treatment [98 courses of pre-highly active antiretroviral therapy (pre-HAART) and 148 HAART treatments]. Liver function tests were assessed at baseline of each treatment, after 1 month and at least every 4 months thereafter. Cytolytic and cholestatic hepatotoxicity was recorded. Of the 246 treatments, 28 (12.45%) were followed by cytolytic hepatotoxicity and 32 (13%) by cholestatic hepatotoxicity. Cytolytic hepatotoxicity was similar in HAART (16/148; 10.8%) and in pre-HAART treatment (12/98; 12.2%) and cholestatic hepatotoxicity was more frequent in HAART (29/148; 19.6%) than in pre-HAART treatment (3/98; 3.1%) (P < 0.001). The actuarial probability of developing cytolytic and cholestatic hepatotoxicity at 10 years of onset of antiretroviral treatments was 39% and 56%, respectively. Most enzyme elevations were asymptomatic, but in eight cases therapy was discontinued or changed and in one case a cirrhotic patient died of progressive liver failure. In HIV HCV haemophiliacs, the cumulative probability of developing hepatotoxicity during follow-up is high and although in the most cases the toxicity is mild, fatal cases can occur.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
1351-8216
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
12
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
228-36
|
| pubmed:dateRevised |
2009-11-19
|
| pubmed:meshHeading |
pubmed-meshheading:16643206-Adolescent,
pubmed-meshheading:16643206-Adult,
pubmed-meshheading:16643206-Anti-Retroviral Agents,
pubmed-meshheading:16643206-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:16643206-Child,
pubmed-meshheading:16643206-Cholestasis,
pubmed-meshheading:16643206-Coagulation Protein Disorders,
pubmed-meshheading:16643206-Drug-Induced Liver Injury,
pubmed-meshheading:16643206-Female,
pubmed-meshheading:16643206-HIV Infections,
pubmed-meshheading:16643206-HIV Protease Inhibitors,
pubmed-meshheading:16643206-Hemophilia A,
pubmed-meshheading:16643206-Hemophilia B,
pubmed-meshheading:16643206-Hepatitis B,
pubmed-meshheading:16643206-Hepatitis C,
pubmed-meshheading:16643206-Humans,
pubmed-meshheading:16643206-Liver Diseases,
pubmed-meshheading:16643206-Liver Function Tests,
pubmed-meshheading:16643206-Male,
pubmed-meshheading:16643206-Middle Aged,
pubmed-meshheading:16643206-Reverse Transcriptase Inhibitors,
pubmed-meshheading:16643206-Risk Factors,
pubmed-meshheading:16643206-von Willebrand Diseases
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at an Haemophilia Unit during a decade.
|
| pubmed:affiliation |
Blood Bank (CTBT), Hospital Vall d'Hebron, Spain.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|